Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Pharma Industry Analysis

UpdatedJun 08, 2026
DataAggregated Company Financials
Companies9
  • 7D2.7%
  • 3M-2.3%
  • 1Y23.8%
  • YTD3.9%

In the last week, the Pharma industry is up 2.7%, with Roche Holding leading the way, up 3.1%. In the last 12 months, the industry was up 24%. Looking forward, earnings are forecast to grow by 11% annually.

Industry Valuation and Performance

Has the Swiss Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 08 Jun 2026CHF 548.0bCHF 122.0bCHF 24.9b38.3x22x4.5x
Wed, 06 May 2026CHF 544.8bCHF 121.0bCHF 24.8b39.9x22x4.5x
Fri, 03 Apr 2026CHF 560.4bCHF 122.3bCHF 25.4b37.9x22.1x4.6x
Sun, 01 Mar 2026CHF 613.6bCHF 119.7bCHF 24.8b37.2x24.8x5.1x
Tue, 27 Jan 2026CHF 591.0bCHF 119.6bCHF 21.2b37.6x27.9x4.9x
Thu, 25 Dec 2025CHF 563.6bCHF 120.6bCHF 21.4b34.5x26.3x4.7x
Sat, 22 Nov 2025CHF 531.9bCHF 122.0bCHF 21.7b35.4x24.5x4.4x
Mon, 20 Oct 2025CHF 503.9bCHF 119.9bCHF 20.9b33.2x24.1x4.2x
Wed, 17 Sep 2025CHF 469.6bCHF 119.5bCHF 20.8b31.2x22.6x3.9x
Fri, 15 Aug 2025CHF 462.2bCHF 121.0bCHF 21.1b30.8x21.9x3.8x
Sun, 13 Jul 2025CHF 449.2bCHF 117.3bCHF 18.9b24.7x23.8x3.8x
Tue, 10 Jun 2025CHF 457.0bCHF 119.0bCHF 19.3b25.8x23.7x3.8x
Thu, 08 May 2025CHF 436.3bCHF 119.0bCHF 19.2b25.6x22.7x3.7x
Sat, 05 Apr 2025CHF 421.7bCHF 120.3bCHF 19.0b25.2x22.2x3.5x
Mon, 03 Mar 2025CHF 480.3bCHF 122.6bCHF 19.2b23.3x25.1x3.9x
Wed, 29 Jan 2025CHF 457.4bCHF 119.4bCHF 21.4b19.2x21.4x3.8x
Fri, 27 Dec 2024CHF 420.4bCHF 119.1bCHF 21.3b17.7x19.7x3.5x
Sun, 24 Nov 2024CHF 434.5bCHF 118.6bCHF 21.3b18.4x20.4x3.7x
Tue, 22 Oct 2024CHF 463.5bCHF 115.9bCHF 19.5b21.9x23.8x4x
Thu, 19 Sep 2024CHF 452.8bCHF 114.7bCHF 19.3b21.7x23.5x3.9x
Sat, 17 Aug 2024CHF 467.7bCHF 115.9bCHF 19.5b22.1x24x4x
Mon, 15 Jul 2024CHF 447.4bCHF 116.1bCHF 19.7b34.6x22.7x3.9x
Wed, 12 Jun 2024CHF 422.8bCHF 116.4bCHF 19.8b43.8x21.4x3.6x
Fri, 10 May 2024CHF 399.3bCHF 113.4bCHF 19.9b40.5x20x3.5x
Sun, 07 Apr 2024CHF 395.4bCHF 112.0bCHF 19.4b37.1x20.4x3.5x
Tue, 05 Mar 2024CHF 388.5bCHF 110.6bCHF 19.7b24.3x19.7x3.5x
Thu, 01 Feb 2024CHF 407.3bCHF 120.1bCHF 18.7b26.1x21.7x3.4x
Sat, 30 Dec 2023CHF 394.8bCHF 118.7bCHF 18.6b25.5x21.3x3.3x
Mon, 27 Nov 2023CHF 393.3bCHF 121.3bCHF 18.9b24.8x20.8x3.2x
Wed, 25 Oct 2023CHF 389.2bCHF 121.0bCHF 18.6b25.6x21x3.2x
Fri, 22 Sep 2023CHF 405.7bCHF 113.0bCHF 18.1b45.7x22.4x3.6x
Sun, 20 Aug 2023CHF 401.9bCHF 111.9bCHF 17.9b47.2x22.4x3.6x
Tue, 18 Jul 2023CHF 406.2bCHF 113.3bCHF 18.6b36.5x21.8x3.6x
Thu, 15 Jun 2023CHF 421.3bCHF 115.2bCHF 18.9b38.1x22.3x3.7x
Price to Earnings Ratio

22.3x


Total Market Cap: CHF 421.3bTotal Earnings: CHF 18.9bTotal Revenue: CHF 115.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Pharma Industry Price to Earnings3Y Average 22.5x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swiss Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 22.5x.
  • The 3-year average PS ratio of 3.9x is lower than the industry's current PS ratio of 4.5x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 9.7% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market0.43%
Healthcare2.27%
Pharma2.73%
Pharma2.73%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ROP Roche HoldingCHF 327.103.1%
+CHF 7.7b		22.0%PE20.2x
NOVN NovartisCHF 117.983.6%
+CHF 7.5b		21.5%PE20x
SDZ Sandoz GroupCHF 64.400.3%
+CHF 77.9m		46.3%PE38.3x
BIOV BioVersysCHF 27.300.7%
+CHF 1.3m		-21.1%PS50.3x
ADXN Addex TherapeuticsCHF 0.0461.3%
+CHF 88.7k		-24.1%PS39.3x

Latest News

NOVN
CHF 117.98
Novartis
7D
3.6%
1Y
21.5%
Narrative Update • Jun 06

NOVN: Broad Pipeline Data And Manufacturing Investments Will Support Balanced Outlook

Analysts have nudged their price target for Novartis higher from CHF 122.04 to CHF 123.55, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E that collectively point to a slightly stronger long term outlook for the stock. What's in the News Pluvicto plus standard of care in PSMA positive metastatic hormone sensitive prostate cancer showed consistent radiographic progression free survival benefits across disease volume and presentation subgroups, along with supportive safety data, at ASCO 2026 and in the Phase 1 AcTION trial for actinium based RLT, reinforcing Novartis' radioligand therapy focus (source: Novartis, ASCO 2026).
COPN
CHF 72.80
Cosmo
7D
-3.2%
1Y
20.9%
Narrative Update • Jun 05

COPN: Alopecia Filings Will Drive CHF 160 Upside Potential

Narrative Update on Cosmo Analysts have raised their price target for Cosmo to CHF 160 from CHF 130, citing updated expectations for revenue growth, profit margins, and future P/E assumptions as key reasons for the change. What's in the News Cosmo reported positive 12 month Phase III results for Clascoterone 5% topical solution in men with mild to moderate androgenetic alopecia, with the program described as the largest Phase III clinical program conducted for a topical treatment in this indication.
ROP
CHF 327.10
Roche Holding
7D
3.1%
1Y
22.0%
GALD
CHF 161.50
Galderma Group
7D
-1.5%
1Y
39.3%
Narrative Update • Jun 03

GALD: Rising Optimism Will Meet Acne Franchise Concentration Risk

Analysts have lifted the Galderma Group price target by about CHF 1 to roughly CHF 183.50, reflecting updated views on fair value, slightly adjusted revenue growth and profit margin assumptions, and continued supportive research commentary across several firms. Analyst Commentary Recent research has focused on how Galderma can execute on its growth plans while justifying higher valuation ranges, with several firms adjusting price targets and ratings in quick succession.
DESN
CHF 295.00
Dottikon ES Holding
7D
-2.0%
1Y
7.5%
SDZ
CHF 64.40
Sandoz Group
7D
0.3%
1Y
46.3%
Narrative Update • May 28

SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E

Analysts have adjusted the Sandoz Group price target slightly higher, with the updated fair value estimate moving from about CHF 66.01 to CHF 66.36 as they factor in modestly different assumptions for growth, margins and future P/E, following a mix of recent upgrades, initiations and target changes across the Street. Analyst Commentary Recent research on Sandoz Group reflects a mix of optimism and caution, with several firms adjusting ratings and price targets in different directions.
NWRN
CHF 12.20
Newron Pharmaceuticals
7D
-6.7%
1Y
58.4%
New Narrative • May 10

Still A Binary Phase III Bet on Evenamide

Rating: Speculative Buy / Clinical-event driven Style: Small-cap biotech with one dominant value driver Core debate: Is Newron an underappreciated CNS biotech on the verge of a value inflection with evenamide, or is it still a one-asset, high-risk Phase III story where financing and trial execution dominate everything else? Executive view Newron is now essentially an evenamide company.
BIOV
CHF 27.30
BioVersys
7D
0.7%
1Y
-21.1%
ADXN
CHF 0.046
Addex Therapeutics
7D
1.3%
1Y
-24.1%
CURN
CHF 22.90
Curatis Holding
7D
-6.1%
1Y
96.6%